Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $13.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target upped by HC Wainwright from $8.00 to $13.00 in a research note published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts also recently weighed in on the company. Rodman & Renshaw raised Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Robert W. Baird reduced their price target on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 25th. Piper Sandler restated an “overweight” rating and issued a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th. Finally, Cantor Fitzgerald assumed coverage on shares of Karyopharm Therapeutics in a research report on Thursday, February 5th. They issued an “overweight” rating for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $16.14.

Karyopharm Therapeutics Trading Down 2.4%

Shares of KPTI stock opened at $8.64 on Wednesday. The company has a market cap of $194.83 million, a PE ratio of -0.52 and a beta of 0.80. The company’s fifty day simple moving average is $7.98 and its 200-day simple moving average is $7.17. Karyopharm Therapeutics has a 52 week low of $3.65 and a 52 week high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.03. The business had revenue of $34.08 million for the quarter, compared to analysts’ expectations of $33.16 million. Equities research analysts expect that Karyopharm Therapeutics will post -4.49 EPS for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KPTI. Hsbc Holdings PLC acquired a new position in shares of Karyopharm Therapeutics in the first quarter worth about $66,000. Corient Private Wealth LLC acquired a new stake in Karyopharm Therapeutics during the 4th quarter valued at approximately $74,000. T. Rowe Price Investment Management Inc. increased its holdings in Karyopharm Therapeutics by 112.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock worth $10,977,000 after purchasing an additional 790,417 shares during the last quarter. Ikarian Capital LLC increased its holdings in Karyopharm Therapeutics by 1,897.9% during the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock worth $4,008,000 after purchasing an additional 517,297 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $95,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.